FDA selects Eli Lilly and Regeneron for PreCheck, targeting up to 14 months sooner reviews

The FDA picked Eli Lilly and Regeneron for its PreCheck program, and the point is painfully specific: the agency estimates the process could save participating companies up to 14 months by reviewing drug manufacturing facilities while they are still under construction. Translation for executives: instead of waiting until a factory is finished and then starting the review clock, the FDA wants to evaluate the facility earlier, during the build phase.

Why that matters is simple. In the real world, manufacturing timelines often become the bottleneck for getting medicines from “almost ready” to “available,” and regulatory reviews can be the calendar friction that costs launches, revenue, and market share. The FDA’s estimate of up to 14 months in time savings is large enough to change how boards and CFOs underwrite projects, how CEOs sequence product development, and how business teams negotiate go-to-market dates.

PreCheck is not just a procedural tweak. It is an attempt to compress the time between a company’s construction plans and the FDA’s facility readiness evaluation. In traditional regulatory workflows, facilities typically undergo review at a stage where construction has already advanced or been completed, which means any issues found then can ripple into remediation and delay the timeline further. By reviewing while construction is ongoing, PreCheck aims to reduce that “late discovery” risk. The FDA’s claim is that this earlier review approach can save up to 14 months for participating companies.

Eli Lilly and Regeneron are notable names to be on the early track. Both operate in areas where manufacturing readiness and timely scaling are central to business outcomes, and both have strong incentives to reduce schedule uncertainty. For leaders, selection into a faster-track FDA process is effectively a bet that the program will be more predictable for timelines than the usual route. It also signals that these companies are prepared to engage with the FDA early in the facility lifecycle, not only once the plant is basically done.

To understand the operational stakes, zoom out to how domestic drug manufacturing decisions get made. Building or upgrading a drug factory is expensive, high-impact, and hard to reverse on short notice. Capital planning depends on when production can start, when regulators can clear the facilities, and when commercial supply can realistically flow. When regulatory review timing is uncertain or extended, companies may either overbuild capacity early (tying up cash) or accept a delayed launch (risking lost revenue and competitive pressure). A program like PreCheck, where the FDA estimates potential time savings of up to 14 months, can move those tradeoffs in a favorable direction.

There is also a strategic boardroom angle. When regulators offer mechanisms to speed up reviews, governance teams tend to reassess project milestones and risk registers. A timeline improvement of that magnitude can change discounting assumptions in underwriting models, alter how much contingency management budgets, and influence how executives stage hiring, vendor contracting, and supply agreements. Even if only participating companies get the benefit, it can still raise expectations across the sector, especially for firms building domestic capacity during the same regulatory cycle.

Second-order implications go beyond the selected companies. If PreCheck works as intended, it pressures peers to ask their own regulatory and manufacturing leadership teams whether early facility engagement is available, whether they can qualify for future rounds, and how their construction plans would need to align to make earlier review feasible. It also may push industry-wide process discipline, because the earlier you invite scrutiny, the more you have to be ready with documentation and compliance readiness throughout the build.

For decision-makers at other drug manufacturers, the message from this selection is not subtle. PreCheck represents a pathway to materially shorter facility review timelines, and the FDA’s estimate of up to 14 months is the headline number that matters. The strategic question is whether faster, earlier review can become a more scalable norm rather than a special track, and what that would mean for the industry’s approach to domestic manufacturing schedules, launch planning, and capital allocation.